TIN Seminar: Medicines agencies pilot to support Repurposing in academia

The aim of this EMA and HMA initiative is to support not-for-profit organisations and academia to generate sufficient evidence on the use of an established medicine in a new indication with the view to have this new use formally authorised by a regulatory authority. This is a way of making new treatment options available to patients.

As part of the pilot, EMA and the national medicines agencies will provide regulatory support, primarily scientific advice, to help these stakeholders generate a data package robust enough to support a future application by a pharmaceutical company.

In this UCL-only seminar, we will:

• Discuss the eligibility criteria to participate in this initiative
• Outline how the Repurposing TIN can assist investigators with the preparation of a proposal to increase chances of funding success
• Identify opportunities for interdisciplinary collaboration, which are likely to enhance the quality of a repurposing plan
• It is anticipated that repurposing programmes endorsed by the EMA will attract interest from pharmaceutical industry and other healthcare organisations. Such an endorsement will also increase probability of success in subsequent applications for grants and funding.

Who Should Attend?

UCL basic and translational researchers at all career stages and currently involved/or planning to work in the Drug Repurposing space are encouraged to attend. As this is a UCL-only event, you must sign up with your UCL email address to gain access.